Agreement to accelerate development of potential treatments for rare, endocrine, metabolic, and neurological conditions associated with primary and secondary ubiquinone deficiencies which belong to the wider class of mitochondrial diseases | An estimated 1 in 5,000 adults worldwide has a mitochondrial disease | Clarus to pay ±«ÓãÖ±²¥ $350,000 upfront and up to $10.5 million in potential development and regulatory milestones
